Use of coagulation factor VII-activating protease for the prophylaxis and therapy of vasoproliferative disorders
OA: closed
Abstract
The use of coagulation factor VII-activating protease (FSAP) for the prophylaxis and/or therapy of vasoproliferative disorders or oncoses is described. Reference is made in particular to the use of the protease for retinopathy, neuropathy, rheumatoid arthritis, psoriasis, endometriosis, bronchitis (especially chronic) or chronic inflammations in the gastrointestinal tract.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-07-07T06:07:59.301721+00:00